Gastritis
71
4
4
43
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.8%
2 terminated out of 71 trials
95.6%
+9.0% vs benchmark
28%
20 trials in Phase 3/4
7%
3 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 43 completed trials
Clinical Trials (71)
Phase 4 Study of Sto M Tab. in Acute or Chronic Gastritis
Vonoprazan High-Dose Dual VS Levofloxacin Concomitant
A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults
Evaluation of Microbial Status in Gastritis Patients in Different Periodontal Conditions
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Establishment and Effectiveness Evaluation of a Training System for Confocal Laser Endomicroscopy
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
Helicobacter Pylori Gastritis and Its Relation to Metabolic Syndrome Components
7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis
Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis
Systems Biology of Gastrointestinal and Related Diseases
MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)
Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis
Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention